down arrow

Artelo Biosciences, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US04301G5080
  • NASDAQ: ARTL
USD
7.31
3.16 (76.14%)

Sep 23

NAS

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Evoke Pharma, Inc.
Cyclacel Pharmaceuticals, Inc.
Bellerophon Therapeutics, Inc.
Jaguar Health, Inc.
Agile Therapeutics, Inc.
SeqLL, Inc.
Hoth Therapeutics, Inc.
Kiora Pharmaceuticals, Inc.
CNS Pharmaceuticals, Inc.
PainReform Ltd.
Artelo Biosciences, Inc.

Why is Artelo Biosciences, Inc. ?

Icon
Unrated Stock - No Analysis Available
stock-recommendationReal-Time Research Report

Verdict Report

Icon
No Data Found

Is Artelo Biosciences, Inc. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Artelo Biosciences, Inc.
-95.31%
0.21
953.26%
S&P 500
15.76%
1.22
13.15%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
0.00%
EBIT Growth (5y)
0.00%
EBIT to Interest (avg)
-6.41
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.71
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
11.74%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-5.87
EV to EBIT
-0.66
EV to EBITDA
-0.66
EV to Capital Employed
-6.14
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

12What is working for the Company
OPERATING PROFIT(Q)

Highest at USD -2.5 MM

PRE-TAX PROFIT(Q)

Highest at USD -2.47 MM

NET PROFIT(Q)

Highest at USD -2.47 MM

RAW MATERIAL COST(Y)

Fallen by 0% (YoY

DEBT-EQUITY RATIO (HY)

Lowest at -83.03 %

EPS(Q)

Highest at USD -8.05

-9What is not working for the Company
INTEREST(HY)

At USD 0.13 MM has Grown at 80.56%

OPERATING CASH FLOW(Y)

Lowest at USD -12.8 MM

Here's what is working for Artelo Biosciences, Inc.

Operating Profit
Highest at USD -2.5 MM and Grown
In each period in the last five periods
MOJO Watch
Near term Operating Profit trend is quite positive

Operating Profit (USD MM)

Pre-Tax Profit
Highest at USD -2.47 MM and Grown
In each period in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (USD MM)

Net Profit
Highest at USD -2.47 MM and Grown
In each period in the last five periods
MOJO Watch
Near term Net Profit trend is very positive

Net Profit (USD MM)

EPS
Highest at USD -8.05
in the last five periods
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Debt-Equity Ratio
Lowest at -83.03 %
in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Artelo Biosciences, Inc.

Interest
At USD 0.13 MM has Grown at 80.56%
over previous Semi-Annual period
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Operating Cash Flow
Lowest at USD -12.8 MM
in the last three years
MOJO Watch
The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Footer loading